Jan 29 (Reuters) - Drugmaker Eli Lilly is partnering with Repertoire Immune Medicines in a deal worth up to $1.93 billion to develop therapies for multiple autoimmune diseases, the Massachusetts-based ...

As part of the deal, Repertoire Immune Medicines will develop up to three drug candidates that target the drivers of certain autoimmune diseases.

Dr. Lacy Anderson says Sjogren’s syndrome is frequently linked to other autoimmune diseases and may also affect the digestive ...

Southeast Alabama experienced a rollercoaster of weather events in a single week, creating additional challenges for ...

The next major drugmaker interested in what Repertoire has to offer is Eli Lilly, which has thrown down $85 million upfront and floated up to $1.84 billion more in biobucks to collaborate on potential ...

Autoimmune neurological diseases are conditions where the immune system attacks nerve cells. Damage to neuronal cells can lead to a variety of neurologic and psychiatric symptoms. Autoimmune diseases ...

Explore the vital role of bone marrow stem cells. Learn how they drive bone remodeling, immunity, and skeletal health in this ...

In the United States about 5%-8% of the population is affected by an autoimmune disorder. Other reports, however, estimate a higher prevalence of various types of autoimmune disorders due to complex ...

People living with an autoimmune disease are nearly twice as likely to suffer from mood problems like depression, anxiety or bipolar disorder, a new large-scale study says. The risk of mood disorders ...

Hormones control essential processes like growth, metabolism, mood, and reproduction, but when their balance is disrupted, it ...

A relatively new class of autoimmune diseases that affect the brain is making psychiatrists rethink some diagnoses.

Biotech stocks are in focus as analysts track upcoming clinical data and regulatory decisions in autoimmune and rare disease ...